Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Clinical trial NCT02142205 · COMPLETED

Trial details

NCT number: NCT02142205
Sponsor: Biogen
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Relapsing-Remitting Multiple Sclerosis

Start date: 2012-05-01
Primary completion: 2013-12-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.